Pharmacogenomics: Challenges and opportunities

被引:166
作者
Roden, Dan M.
Altman, Russ B.
Benowitz, Neal L.
Flockhart, David A.
Giacomini, Kathleen M.
Johnson, Julie A.
Krauss, Ronald M.
McLeod, Howard L.
Ratain, Mark J.
Relling, Mary V.
Ring, Huijun Z.
Shuldiner, Alan R.
Weinshilboum, Richard M.
Weiss, Scott T.
机构
[1] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA
[2] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Indiana Univ, Indianapolis, IN 46204 USA
[5] Univ Florida, Gainesville, FL USA
[6] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA
[7] Univ N Carolina, Chapel Hill, NC 27515 USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[10] SRI Int, Menlo Pk, CA 94025 USA
[11] Univ Maryland, Baltimore, MD 21201 USA
[12] Mayo Clin, Rochester, MN USA
[13] Channing Labs, Boston, MA USA
基金
英国惠康基金;
关键词
D O I
10.7326/0003-4819-145-10-200611210-00007
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The outcome of drug therapy is often unpredictable, ranging from beneficial effects to lack of efficacy to serious adverse effects. Variations in single genes are 1 well-recognized cause of such unpredictability, defining the field of pharmacogenetics (see Glossary). Such variations may involve genes controlling drug metabolism, drug transport, disease susceptibility, or drug targets. The sequencing of the human genome and the cataloguing of variants across human genomes are the enabling resources for the nascent field of phafmacogenomics (see Glossary), which tests the idea that genomic variability underlies variability in drug responses. However, there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways; relating disease genes to drug response genes; precisely defining drug response phenotypes; and addressing analytic, ethical, and technological issues involved in generation and management of large drug response data sets. Overcoming these challenges holds the promise of improving new drug development and ultimately individualizing the selection of appropriate drugs and dosages for individual patients.
引用
收藏
页码:749 / 757
页数:9
相关论文
共 78 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   A haplotype map of the human genome [J].
Altshuler, D ;
Brooks, LD ;
Chakravarti, A ;
Collins, FS ;
Daly, MJ ;
Donnelly, P ;
Gibbs, RA ;
Belmont, JW ;
Boudreau, A ;
Leal, SM ;
Hardenbol, P ;
Pasternak, S ;
Wheeler, DA ;
Willis, TD ;
Yu, FL ;
Yang, HM ;
Zeng, CQ ;
Gao, Y ;
Hu, HR ;
Hu, WT ;
Li, CH ;
Lin, W ;
Liu, SQ ;
Pan, H ;
Tang, XL ;
Wang, J ;
Wang, W ;
Yu, J ;
Zhang, B ;
Zhang, QR ;
Zhao, HB ;
Zhao, H ;
Zhou, J ;
Gabriel, SB ;
Barry, R ;
Blumenstiel, B ;
Camargo, A ;
Defelice, M ;
Faggart, M ;
Goyette, M ;
Gupta, S ;
Moore, J ;
Nguyen, H ;
Onofrio, RC ;
Parkin, M ;
Roy, J ;
Stahl, E ;
Winchester, E ;
Ziaugra, L ;
Shen, Y .
NATURE, 2005, 437 (7063) :1299-1320
[3]  
Ando Y, 2000, CANCER RES, V60, P6921
[4]  
[Anonymous], 1923, Inborn Errors of Metabolism
[5]   Genetic nondiscrimination [J].
Billings P.R. .
Nature Genetics, 2005, 37 (6) :559-560
[6]   Pharmacogenetics: ethical problems and solutions [J].
Breckenridge, A ;
Lindpaintner, K ;
Lipton, P ;
McLeod, H ;
Rothstein, M ;
Wallace, H .
NATURE REVIEWS GENETICS, 2004, 5 (09) :676-680
[7]  
Caraco Y, 1999, J PHARMACOL EXP THER, V290, P413
[8]   Pharmacogenetic study of statin therapy and cholesterol reduction [J].
Chasman, DI ;
Posada, D ;
Subrahmanyan, L ;
Cook, NR ;
Stanton, VP ;
Ridker, PM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (23) :2821-2827
[9]   Mathematics is biology's next microscope, only better; Biology is mathematics' next physics, only better [J].
Cohen, JE .
PLOS BIOLOGY, 2004, 2 (12) :2017-2023
[10]  
Couzin J, 2004, SCIENCE, V305, P1222